(HealthDay News) — Tofacitinib is associated with improvements in nail psoriasis, according to a study published in the the Journal of the American Academy of Dermatology. Joseph F. Merola, MD, from ...

Tofacitinib reversed baldness in a 25-year-old man with plaque psoriasis and alopecia universalis. The rheumatoid arthritis drug reduced the bright red patches on the man's skin and restored a full ...

SAN FRANCISCO — New findings on experimental options for plaque psoriasis were debated here at the American Academy of Dermatology 73rd Annual Meeting. The biologic agents appear to be easing symptoms ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults with psoriatic disease. Older systemic medications, including methotrexate, ...

The FINANCIAL — Pfizer Inc. announced on October 14 it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for ...

Please provide your email address to receive an email when new articles are posted on . An analysis of more than 880,000 post-marketing reports found that all TNF inhibitors demonstrate a ...

F rom topicals and light therapy to systemic medications, a variety of treatments are available to treat psoriasis. Because each option is unique, some will work better for you than others. A ...

(Reuters) - U.S. health regulators declined to approve Pfizer Inc's oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker ...

Small molecule therapies. Apremilast is a small, oral phosphodiesterase-4 (PDE4) inhibitor effective for the treatment of psoriasis and psoriatic arthritis; 2 it showed a minimum 75% reduction in PASI ...